GLP-1 medications like semaglutide (the active ingredient in Wegovy & Ozempic) can be powerful tools for improving insulin resistance and supporting weight loss in PCOS
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
In another preclinical study, GE demonstrated superior metabolic effects compared to GLP-1-GIP or GLP-1-GIP-glucagon multiagonist therapies in models of polycystic ovary syndrome (PCOS), a condition frequently associated with obesity and insulin resistance
Exendin-4 (Ex-4), another GLP-1RA that is homologous to commercially available exenatide, ameliorated IR in primary neurons through insulin receptor substrate-1 (IRS-1), AKT, and glycogen synthase kinase-3 (GSK-3) pathways
It offers an alternative for those averse to injections but has different absorption rates and pharmacokinetic properties that may affect its efficacy and side effect profile
Em 2026, o retatrutide esta em desenvolvimento de Fase III pela Eli Lilly e nao foi aprovado pela FDA ou EMA como medicamento